Joshua Stern
This open-label pilot study evaluates whether oral microbial transplant therapy can change urine factors associated with recurrent calcium-oxalate kidney stones. Adults with high urine calcium or high urine oxalate will receive antibiotic pretreatment followed by microbial capsules. Changes in 24-hour urine calcium and oxalate and treatment safety will be assessed.
Participants with recurrent calcium-oxalate stones are assigned to a hyperoxaluric or hypercalciuric cohort based on baseline 24-hour urine results. All participants receive vancomycin 500 mg twice daily and neomycin 1,000 mg twice daily for 3 days. Forty-eight to 72 hours later, they take 2 microbial transplant therapy capsules daily for 7 days. Urine and stool samples are collected at baseline, after antibiotics, and during follow-up. Participants serve as their own controls. Follow-up includes weekly contacts through Week 5, telephone/record review at Months 2-6, and record review at Months…
Inclusion Criteria: * Age 18 years or older and younger than 70 years. * Recent urinary stone disease with at least 50% calcium-oxalate composition confirmed by stone analysis. * 24-hour urinary calcium \>225 mg/day or urinary oxalate \>40 mg/day. * Able to provide informed consent. * Willing to complete safety follow-up, study visits, 24-hour urine collections, and serial stool collections. * Not actively participating in another interventional urinary stone disease trial. * eGFR \>=60. Exclusion Criteria: * Three or more NIH-defined metabolic syndrome features. * Any autoimmune disease or…
Two capsules orally once daily for 7 days, beginning 48-72 hours after completion of antibiotic pretreatment.
Vancomycin 500 mg orally twice daily and neomycin 1,000 mg orally twice daily for 3 days before MTT.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.